ArticleAnimals : an open access journal from MDPI2026
Effects of In Ovo Injection of Mannan-Oligosaccharides on Early Growth Performance, Intestinal Morphology, and Cecal Microbiota in Broilers.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mannan oligosaccharides (MOS) are functional prebiotics that selectively promote the proliferation of beneficial bacteria in the chicken intestinal tract. This study evaluated the effects of in ovo MOS injection on early growth, intestinal morphology, and cecal microbiota of broilers at 7, 14, and 21 days post-hatch (dph). In total, 700 Cobb 500 fertilized eggs received either no injection or 200 μL of PBS diluent, low (0.5 mg/egg), medium (5 mg/egg), or high (10 mg/egg) doses of MOS in the amnion. At hatch, approximately 280 male hatchlings from injection groups were distributed into 28 cages and raised until 21 dph. Our results indicated that MOS injection linearly increased feed intake and body weight during 0-7 dph and improved duodenal villus height and width, with no persistent improvements observed at older age. Moreover, microbiota shifts triggered by MOS were only observed at 7 dph. The MOS injection at 0.5 mg/egg reduced genus-level Sobs, and PCoA coupled with ADONIS analysis confirmed microbial separation across treatments (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.